Skip to main content

Table 1 Characteristics of the study participants grouped by the presence of NPS at baseline

From: Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression

  

total

n = 151

 

NPS +

n = 72

 

NPS -

n = 79

 

p

Demographic data

        

 sex, female (%)

 

85 (56.3)

 

35 (48.6)

 

50 (63.3)

 

0.074

 age, years

 

71.0 ± 7.4

 

72.3 ± 6.3

 

69.8 ± 8.1

 

0.034

 education, years

 

12.8 ± 2.7

 

12.5 ± 3.0

 

13.0 ± 2.5

 

0.315

Clinical data

        

 cognitive status, impaired (%)

 

77 (55.4)

 

49 (76.6)

 

26 (32.9)

 

< 0.001

 CDR

 

0.2 ± 0.3

 

0.3 ± 0.2

 

0.2 ± 0.2

 

< 0.001

 CDR-SB

 

0.7 ± 1.0

 

1.2 ± 1.2

 

0.3 ± 0.6

 

< 0.001

 MMSE

 

27.3 ± 2.9

 

27.9 ± 2.8

 

26.5 ± 3.0

 

< 0.001

CSF AD profile (%)

 

59 (39.3)

 

42 (59.2)

 

17 (21.5)

 

< 0.001

APOEe4 carrier (%)

 

55 (34.7)

 

31 (45.6)

 

19 (25.0)

 

0.014

plasma pTau181 (pg/ml)

 

12.7 ± 10.6

 

13.7 ± 9.9

 

11.8 ± 11.2

 

0.063

plasma NfL (pg/ml)

 

21.0 ± 13.8

 

22.9 ± 17.4

 

19.2 ± 9.2

 

0.208

plasma GFAP (pg/ml)

 

10.8 ± 4.6

 

11.3 ± 4.5

 

10.4 ± 4.7

 

0.171

time to follow-up (months)

 

20.7 ± 8.0

 

19.9 ± 7.6

 

21.4 ± 8.3

 

0.233

  1. Description: Criteria for the NPS positive group (NPS +) were NPI-Q score > 0, for the NPS negative group (NPS -) NPI-Q score = 0. Mean values ± standard deviation are shown. A positive AD profile was defined based on a center cut-off of pTau181/Aβ42 ratio > 0.078. Cognitive impairment was defined as CDR = 0.5. Aβ42, beta-amyloid 1–42 peptide; APOEe4, Apolipoprotein E epsilon 4; AD, Alzheimer’s disease; CDR, clinical dementia rating; CDR-SB, clinical dementia rating sum-of-boxes; GFAP, glial fibrillary acid protein; MMSE, mini mental status examination; n, number; NfL, neurofilament light chain; NPI-Q, neuropsychiatric inventory questionnaire; NPS, neuropsychiatric symptoms; pTau181, tau phosphorylated at threonine 181
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193